Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353340 | 0.89 | HDAC1 (0.52) | HDAC1JAK2HDAC3HDAC2HDAC4 | |
| SCHEMBL656876 | 0.88 | HDAC1 (0.39) | HDAC1JAK2HDAC3HDAC2HDAC8 | |
| SCHEMBL657217 | 0.88 | HDAC1 (0.48) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL657692 | 0.83 | HDAC1 (0.52) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL657226 | 0.82 | HDAC1 (0.53) | HDAC1JAK2HDAC3HDAC2HDAC4 | |
| SCHEMBL3356670 | 0.80 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC11HDAC8 | |
| SCHEMBL3348244 | 0.79 | HDAC1 (0.53) | HDAC1HDAC3HDAC2 | |
| SCHEMBL3350582 | 0.77 | HDAC1 (0.47) | HDAC1HDAC3HDAC2HDAC4HDAC7 | |
| SCHEMBL3348703 | 0.76 | HDAC1 (0.43) | HDAC1JAK2HDAC3HDAC2HDAC4 | |
| SCHEMBL197893 | 0.75 | HDAC1 (0.46) | HDAC1HDAC3HDAC2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045412-A1 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885JAK2 1996/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.